AbbVie Inc (ABBV)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)
ABBV
AbbVie Inc
$258.09
-1.81%
HEALTHCARE · Cap: $442.36B
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$11.73
-1.92%
HEALTHCARE · Cap: $1.19B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6071% more annual revenue ($64.39B vs $1.04B). ABBV leads profitability with a 9.8% profit margin vs -2.7%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
LMRI
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$258.08
$106.59 premium
Intrinsic value data unavailable for LMRI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 3.2%
ROE of -10.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : LMRI
The strongest argument for LMRI centers on Debt/Equity, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : LMRI
The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while LMRI is a turnaround play — different risk/reward profiles.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Lumexa Imaging Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?